Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.79 - $15.68
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.77M
Enterprise Value$4.71M
Total Cash (Recent Filing)$88.00K
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
Beta1.79
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.32
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap1.70
Enterprise Value/Revenue5.75
Enterprise Value/Gross Profit20.65
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsSustained ~90%+ gross margins indicate strong product-level economics for the mapping catheter business. Durable per-procedure pricing and low COGS provide a structural ability to generate high contribution margins as volumes scale, supporting eventual operating leverage if revenue growth continues.
Improving Revenue TrendSequential top-line improvement shows early traction for the core electrophysiology product set. A multi-month trend of revenue growth, even off a small base, suggests growing clinical adoption and incremental procedure-based sales that can compound over time and underpin a commercial ramp.
Material Financing And Liability ConversionConverting royalty obligations and arranging institutional financing materially improves liquidity and reduces recurring royalty cash outflows. These structural balance-sheet moves extend runway, align long-term institutional capital and provide flexibility to fund restructuring or targeted growth initiatives over coming months.
Bears Say
Heavy Cash Burn & Deep LossesLarge operating and net losses relative to revenue reflect an unsustainable cash-consuming model absent rapid revenue scale. Persistent negative operating and free cash flow force reliance on external capital, increasing execution risk and raising the probability of dilution or strategic restructuring over months.
Strategic Pivot Into AviationMoving into aviation and consolidating Flyte shifts focus from the firm's core electrophysiology device expertise. This structural pivot reallocates capital and management attention to a different industry with distinct operational, regulatory and capital requirements, raising execution and strategic-coherence risks.
Dilution & Complex Capital StructureIssuing multiple convertible preferred series with variable conversion terms, royalty-to-equity exchanges and reverse-split authority creates a path to substantial common-share dilution. This structural capital complexity can compress existing equity value and complicate governance and incentive alignment over the medium term.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.79 and its highest was $15.68 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.77M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is May 11, 2026 which is in 22 days.
How were Catheter Precision’s earnings last quarter?
Catheter Precision released its earnings results on Mar 31, 2026. The company reported -$3.323 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.323.
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 2,692,473 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Catheter Precision reported an EPS of -$3.323 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.81%.
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Technical Analysis
Ownership Overview
0.84%
Insiders
0.17% Mutual Funds
<0.01% Other Institutional Investors
98.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---